Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term aspirin therapy and susceptibility to SARS-CoV-2 infection in aspirin-exacerbated respiratory disease
2024-514602-31-00Phase 3Completed
- Sponsor
- Jagiellonian University Medical College
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of aspirin in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD) (2 arms), sponsored by Jagiellonian University Medical College. Started Jul 2024; status: completed.
02
Drugs
aspirin
03
Conditions
nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)
Beyond the preview
Go deeper on 2024-514602-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514602-31-00.